Wolf, Katrin

[["dc.bibliographiccitation.firstpage","366"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Experimental Neurology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","223"],["dc.contributor.author","Lewczuk, Piotr"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Vanmechelen, Eugeen"],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Heuser, Isabella"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Jessen, Frank"],["dc.contributor.author","Buerger, Katharina"],["dc.contributor.author","Hampel, Harald"],["dc.contributor.author","Froelich, Lutz"],["dc.contributor.author","Henn, Fritz A."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Jahn, Holger"],["dc.contributor.author","Luckhaus, C. H."],["dc.contributor.author","Perneczky, Robert"],["dc.contributor.author","Schmidtke, K."],["dc.contributor.author","Schroeder, J."],["dc.contributor.author","Kessler, H."],["dc.contributor.author","Pantel, Johannes"],["dc.contributor.author","Gertz, H.-J."],["dc.contributor.author","Vanderstichele, Hugo"],["dc.contributor.author","de Meyer, G."],["dc.contributor.author","Shapiro, F."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Bibl, Mirko"],["dc.contributor.author","Wiltfang, J."],["dc.date.accessioned","2018-11-07T08:42:36Z"],["dc.date.available","2018-11-07T08:42:36Z"],["dc.date.issued","2010"],["dc.description.abstract","We measured concentrations of to peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for A beta 1-42, and 1.8-4.1% for A beta 1-40, inter-assay imprecision for A beta 1-42, A beta 1-40, and A beta 1-42/A beta 1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 42-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n = 193) had significantly lower A beta 1-42 plasma concentrations (p<0.007), and A beta 1-42/1-40 ratios (p<0.003) compared to patients with other dementias and MCI of other types (n = 64). No significant differences between persons with MCI of AD type and patients with early AD were observed, or between MCI of other types versus patients with early dementia of other types. Our findings reconfirm the hypothesis that alterations of biomarker concentrations occur early in a preclinical AD stage and that these alterations are also reflected in plasma. (C) 2009 Published by Elsevier Inc."],["dc.identifier.doi","10.1016/j.expneurol.2009.07.024"],["dc.identifier.isi","000277743700015"],["dc.identifier.pmid","19664622"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19739"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Academic Press Inc Elsevier Science"],["dc.relation.issn","0014-4886"],["dc.title","Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","379"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","386"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Wagner, M."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Reischies, Friedel M."],["dc.contributor.author","Daerr, M."],["dc.contributor.author","Wolfsgruber, S."],["dc.contributor.author","Jessen, Frank"],["dc.contributor.author","Popp, J."],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Huell, Michael"],["dc.contributor.author","Froelich, Lutz"],["dc.contributor.author","Hampel, Harald"],["dc.contributor.author","Perneczky, Robert"],["dc.contributor.author","Peters, Oliver"],["dc.contributor.author","Jahn, Holger"],["dc.contributor.author","Luckhaus, C."],["dc.contributor.author","Gertz, H.-J."],["dc.contributor.author","Schroeder, J."],["dc.contributor.author","Pantel, Johannes"],["dc.contributor.author","Lewczuk, Piotr"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Wiltfang, J."],["dc.date.accessioned","2018-11-07T09:13:50Z"],["dc.date.available","2018-11-07T09:13:50Z"],["dc.date.issued","2012"],["dc.description.abstract","Objective: To compare cued recall measures with other memory and nonmemory tests regarding their association with a biomarker profile indicative of Alzheimer disease (AD) in CSF among patients with mild cognitive impairment (MCI). Methods: Data were obtained by the German Dementia Competence Network. A total of 185 memory clinic patients fulfilling broad criteria for MCI (1 SD deficit in memory tests or in nonmemory tests) were assessed with an extended neuropsychological battery, which included the Free and Cued Selective Reminding Test (FCSRT), the word list learning task from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD-NP), and the Logical Memory (LM) paragraph recall test from the Wechsler Memory Scale-Revised. CSF was obtained from all patients. Results: A total of 74 out of 185 subjects with MCI (40%) had a CSF profile consistent with AD (A beta(1-42)/tau ratio; CSF AD + group). FCSRT measures reflecting both free and cued recall discriminated best between CSF AD + and CSF AD - patients, and significantly improved CSF AD classification accuracy, as compared with CERAD delayed recall and LM delayed recall. Conclusions: Cued recall deficits are most closely associated with CSF biomarkers indicative of AD in subjects with MCI. This novel finding complements results from prospective clinical studies and provides further empirical support for cued recall as a specific indicator of prodromal AD, in line with recently proposed research criteria. Neurology (R) 2012; 78: 379-386"],["dc.identifier.doi","10.1212/WNL.0b013e318245f447"],["dc.identifier.isi","000300392000007"],["dc.identifier.pmid","22238414"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27260"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1973"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Biology of Reproduction"],["dc.bibliographiccitation.lastpage","1978"],["dc.bibliographiccitation.volume","69"],["dc.contributor.author","Nayernia, K."],["dc.contributor.author","Drabent, B."],["dc.contributor.author","Adham, Ibrahim M."],["dc.contributor.author","Moschner, M."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Meinhardt, Andreas"],["dc.contributor.author","Engel, Wolfgang"],["dc.date.accessioned","2018-11-07T10:34:15Z"],["dc.date.available","2018-11-07T10:34:15Z"],["dc.date.issued","2003"],["dc.description.abstract","In recent years, much knowledge about the functions of defined genes in spermatogenesis has been gained by making use of mouse transgenic and gene knockout models. Single null mutations in mouse genes encoding four male germ cell proteins, transition protein 2 (Tnp-2), proacrosin (Acr), histone H1.1 (H1.1), and histone H1t (H1t), have been generated and analyzed. Tnp-2 is believed to participate in the removal of the nuclear histones and initial condensation of the spermatid nucleus. Proacrosin is an acrosomal protease synthesized as a proenzyme and activated into acrosin during the acrosome reaction. The linker histone subtype H1.1 belongs to the group of main-type histones and is synthesized in somatic tissues and germ cells during the S-phase of the cell cycle. The histone gene H1t is expressed exclusively in spermatocytes and may have a function in establishing an open chromatin structure for the replacement of histones by transition proteins and protamines. Male mutant mice lacking any of these proteins show no apparent defects in spermatogenesis or fertility. To examine the synergistic effects of these proteins in spermatogenesis and during fertilization, two lines of triple null mice (Tnp-2(-/-)/Acr(-/-)/H1.1(-/-) and Tnp-2(-/-)/Acr(-1-)/H1t(-/-)) were established. Both lines are fertile and show normal sperm parameters, which clearly demonstrate the functional redundancy of these proteins in male mouse fertility. However, sperm only deficient for Acr (Acr(-/-)) are able to compete significantly with sperm from triple knockout mice Tnp-2(-/-)/Acr(-/-)/H1.1(-/-) (70.7% vs. 29.3%) but not with sperm from triple knockout mice Tnp-2(-/-)/Acr(-/-)/H1t(-/-) (53.6% vs. 46.4%). These results are consistent with a model that suggests that some sperm proteins play a role during sperm competition."],["dc.identifier.doi","10.1095/biolreprod.103.018564"],["dc.identifier.isi","000186772300028"],["dc.identifier.pmid","12930723"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44819"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Soc Study Reproduction"],["dc.relation.issn","0006-3363"],["dc.title","Male mice lacking three germ cell expressed genes are fertile"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","343"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","CYBERPSYCHOLOGY & BEHAVIOR"],["dc.bibliographiccitation.lastpage","349"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Kesztyues, T. I."],["dc.contributor.author","Mehlitz, M."],["dc.contributor.author","Schilken, E."],["dc.contributor.author","Weniger, Godehard"],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Piccolo, U."],["dc.contributor.author","Irle, Eva"],["dc.contributor.author","Rienhoff, Otto"],["dc.date.accessioned","2018-11-07T10:46:50Z"],["dc.date.available","2018-11-07T10:46:50Z"],["dc.date.issued","2000"],["dc.description.abstract","The University of Goettingen the Interdisciplinary Virtual Reality Research Group developed a neuropsychological test system that was supported by virtual reality (VR). The test system was designed in order to evaluate VR technology for the diagnostics of neuropsychological orientation disorders. To identify application problems, a preclinical evaluation study has been done. Side effects and task performance have been documented and analyzed for 22 probands. Focusing on side effects, we evaluated the difference between two projection modalities (head mounted display [HMD] and one-wall projection [OWP]). Furthermore two different VR environments (maze and park) were applied. The VR system demonstrated a good overall functionality, only a few problems occurred during the tests with the HMD. In regard to simulator sickness, a higher level of simulator sickness was observed in the HMD group. All other parameters did not differ substantially. Our VR-system with the neuropsychological tests for orientation disorders proved to be suitable for testing patients under controlled conditions. However, the application of VR-environments in clinical use with patients needs further investigation."],["dc.identifier.doi","10.1089/10949310050078788"],["dc.identifier.isi","000168235800007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47834"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc Publ"],["dc.publisher.place","Larchmont"],["dc.relation.conference","Virtual Reality and Mental Health Symposium"],["dc.relation.eventlocation","NEWPORT BEACH, CALIFORNIA"],["dc.relation.issn","1094-9313"],["dc.title","Preclinical evaluation of a virtual reality neuropsychological test system: Occurrence of side effects"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","155"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","MHR Basic science of reproductive medicine"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Jaroszynski, L."],["dc.contributor.author","Dev, A."],["dc.contributor.author","Li, M."],["dc.contributor.author","Meinhardt, Andreas"],["dc.contributor.author","de Rooij, D. G."],["dc.contributor.author","Mueller, Christian"],["dc.contributor.author","Boehm, Detlef"],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Adham, Ibrahim M."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Engel, Wolfgang"],["dc.contributor.author","Nayernia, K."],["dc.date.accessioned","2018-11-07T11:04:40Z"],["dc.date.available","2018-11-07T11:04:40Z"],["dc.date.issued","2007"],["dc.description.abstract","Testis expressed gene 18 (Tex18) is a small gene with one exon of 240 bp, which is specifically expressed in male germ cells. The gene encodes for a protein of 80 amino acids with unknown domain. To investigate the function of (Tex18) gene, we generated mice with targeted disruption of the (Tex18) gene by homologous recombination. Homozygous mutant males on a mixed genetic background (C57BL/6J x 129/Sv) are fertile, while they are subfertile on the 129/Sv background, although mating is normal. We showed that Tex18(-/-) males are subfertile because of abnormal sperm morphology and reduced motility, which is called asthenoteratozoospermia, suggesting that (Tex18) affects sperm characteristics. Maturation of spermatids is unsynchronized and partially impaired in seminiferous tubules of Tex18(-/-) mice. Electron microscopical examination demonstrated abnormal structures of sperm head. In vivo experiments with sperm of Tex18(-/-) 129/Sv mice revealed that the migration of spermatozoa from the uterus into the oviduct is reduced. This result is supported by the observation that sperm motility, as determined by the computer-assisted semen analysis system, is significantly affected, compared to wild-type spermatozoa. Generation of transgenic mice containing Tex18-EGFP fusion construct revealed a high transcriptional activity of (Tex18) during spermiogenesis, a process with morphological changes of haploid germ cells and development to mature spermatozoa. These results indicate that (Tex18) is expressed predominantly during spermatid differentiation and subfertility of the male Tex18(-/-) mice on the 129/Sv background is due to the differentiation arrest, abnormal sperm morphology and reduced sperm motility."],["dc.identifier.doi","10.1093/molehr/gal107"],["dc.identifier.isi","000244662300003"],["dc.identifier.pmid","17208930"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51894"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1360-9947"],["dc.title","Asthenoteratozoospermia in mice lacking testis expressed gene 18 (Tex18)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","310C"],["dc.bibliographiccitation.issue","1-3"],["dc.bibliographiccitation.journal","Nuclear Physics A"],["dc.bibliographiccitation.lastpage","313C"],["dc.bibliographiccitation.volume","690"],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Lisin, V."],["dc.contributor.author","Kondratiev, R."],["dc.contributor.author","Massone, A. M."],["dc.contributor.author","Galler, G."],["dc.contributor.author","Ahrens, J."],["dc.contributor.author","Arends, H. J."],["dc.contributor.author","Beck, R."],["dc.contributor.author","Camen, M."],["dc.contributor.author","Capitani, G. P."],["dc.contributor.author","Grabmayr, P."],["dc.contributor.author","Hall, S. J."],["dc.contributor.author","Harter, Frauke V."],["dc.contributor.author","Hehl, T."],["dc.contributor.author","Jennewein, P."],["dc.contributor.author","Kossert, K."],["dc.contributor.author","L'vov, A. I."],["dc.contributor.author","Molinari, C."],["dc.contributor.author","Ottonello, P."],["dc.contributor.author","Peise, J."],["dc.contributor.author","Preobrajenskij, I."],["dc.contributor.author","Proff, S."],["dc.contributor.author","Robbiano, A."],["dc.contributor.author","Sanzone, M."],["dc.contributor.author","Schumacher, M."],["dc.contributor.author","Schmitz, M."],["dc.contributor.author","Wissmann, F."],["dc.date.accessioned","2018-11-07T08:58:23Z"],["dc.date.available","2018-11-07T08:58:23Z"],["dc.date.issued","2001"],["dc.identifier.isi","000169591100043"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23630"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.eventlocation","DARMSTADT UNIV TECH, LICHTENBERG BLDG, DARMSTADT, GERMANY"],["dc.relation.issn","0375-9474"],["dc.title","Structure of the nucleon investigated by Compton scattering"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","766"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Nature Geoscience"],["dc.bibliographiccitation.lastpage","769"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Martinson, Guntars O."],["dc.contributor.author","Werner, Florian A."],["dc.contributor.author","Scherber, Christoph"],["dc.contributor.author","Conrad, Ralf"],["dc.contributor.author","Corre, Marife D."],["dc.contributor.author","Flessa, Heiner"],["dc.contributor.author","Wolf, Katrin"],["dc.contributor.author","Klose, Melanie"],["dc.contributor.author","Gradstein, S. Robbert"],["dc.contributor.author","Veldkamp, Edzo"],["dc.date.accessioned","2017-09-07T11:43:35Z"],["dc.date.available","2017-09-07T11:43:35Z"],["dc.date.issued","2010"],["dc.description.abstract","Methane is a potent greenhouse gas1. Methane concentrations above neotropical forests—the tropical forests found in Mexico, Central America, South America and the Caribbean—are high according to space-borne observations. However, the source of the methane is uncertain2,3. Here, we measure methane fluxes from tank bromeliads—a common group of herbaceous plants in neotropical forests that collect water in tank-like structures—using vented static chambers. We sampled 167 bromeliads in the Ecuadorian Andes, and found that all of them emitted methane. We found a diverse community of methane-producing archaea within the water-containing tanks, suggesting that the tanks served as the source of the methane. Indeed, tank water was supersaturated with methane, and 13C-labelled methane added to tank water was emitted though the leaves. We suggest that the bromeliad tanks form a wetland environment conducive to methane production. In conjunction with other wetlands hidden beneath the copy surface, bromeliads may help to explain the inexplicably high methane levels observed over neotropical forests."],["dc.identifier.doi","10.1038/ngeo980"],["dc.identifier.gro","3150171"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6906"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.relation.issn","1752-0894"],["dc.title","Methane emissions from tank bromeliads in neotropical forests"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","671"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","680"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Bibl, Mirko"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Lewczuk, Piotr"],["dc.contributor.author","Esselmann, Herrmann"],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Stiens, G."],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Wiltfang, J."],["dc.date.accessioned","2018-11-07T11:01:11Z"],["dc.date.available","2018-11-07T11:01:11Z"],["dc.date.issued","2007"],["dc.description.abstract","Biomarkers for differential diagnosis of the three most frequent degenerative forms of dementia, Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and frontotemporal dementias (FTD), are currently under intensive investigation, but disease-specific biomarkers for FTD and DLB are still lacking. We analyzed 303 cerebrospinal fluid (CSF) samples of 71 AD, 32 DLB and 36 FTD patients in comparison to 93 various other dementias (OD), 20 peripheral neurologic disease (PND) controls, 25 neurodegenerative disorders without dementia (ND) and 26 depressive cognitive complainers (DCC) for distinct CSF amyloid-beta (Ab) peptide patterns, using the quantitative A beta-SDS-PAGE/immunoblot. Additionally, the novel electrochemiluminescence technique (MSD) was used to validate the measures on A beta 1-38. The main outcome measures were a striking decrease of A beta 1-42 in AD ( P = 7.4 x 10(-19)), and most interestingly a pronounced decrease of A beta 1-38 in FTD ( P = 9.6 x 1 0(-7)). Moreover, a novel peptide that most probably represents an oxidized alpha-helical form of A beta 1-40 (A beta 1-40(ox)) displayed a highly significant increase in DLB ( P = 3.7 x 10(-3)) as compared to non-demented disease controls. The overall diagnostic accuracy of percentage Ab peptide abundances (A beta 1-X%) was clearly superior to absolute CSF Ab levels. A beta 1-42% and A beta 1-38% enabled contrasts of 85% or beyond to distinguish AD and FTD, respectively, from all other investigated subjects. A beta 1-40(ox)% yielded a diagnostic sensitivity and specificity of 88 and 73% for the detection of DLB among all other investigated patients. We found a strong correlation between A beta 1-38 levels as measured by the A beta-SDS-PAGE/immunoblot and MSD, respectively. CSF A beta peptides may reflect disease-specific impact of distinct neurodegenerative processes on A beta peptide metabolism and represent a potential diagnostic biomarker for AD, FTD and DLB."],["dc.identifier.doi","10.1038/sj.mp.4001967"],["dc.identifier.isi","000247619700009"],["dc.identifier.pmid","17339876"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51089"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1359-4184"],["dc.title","Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","245"],["dc.bibliographiccitation.issue","3-4"],["dc.bibliographiccitation.journal","Physics Letters B"],["dc.bibliographiccitation.lastpage","255"],["dc.bibliographiccitation.volume","503"],["dc.contributor.author","Galler, G."],["dc.contributor.author","Lisin, V."],["dc.contributor.author","Kondratiev, R."],["dc.contributor.author","Massone, A. M."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Ahrens, J."],["dc.contributor.author","Arends, H. J."],["dc.contributor.author","Beck, R."],["dc.contributor.author","Camen, M."],["dc.contributor.author","Capitani, G. P."],["dc.contributor.author","Grabmayr, P."],["dc.contributor.author","Hall, S. J."],["dc.contributor.author","Harter, Frauke V."],["dc.contributor.author","Hehl, T."],["dc.contributor.author","Jennewein, P."],["dc.contributor.author","Kossert, K."],["dc.contributor.author","L'vov, A. I."],["dc.contributor.author","Molinari, C."],["dc.contributor.author","Ottonello, P."],["dc.contributor.author","Peise, J."],["dc.contributor.author","Preobrajenski, I."],["dc.contributor.author","Proff, S."],["dc.contributor.author","Robbiano, A."],["dc.contributor.author","Sanzone, M."],["dc.contributor.author","Schumacher, M."],["dc.contributor.author","Schmitz, M."],["dc.contributor.author","Wissmann, F."],["dc.date.accessioned","2018-11-07T09:15:53Z"],["dc.date.available","2018-11-07T09:15:53Z"],["dc.date.issued","2001"],["dc.description.abstract","Compton scattering by the proton has been measured over a wide range covering photon energies 250 MeV less than or similar to E-gamma less than or similar to 800 MeV and photon scattering angles 30 degrees less than or similar to theta (lab)(gamma) less than or similar to 150 degrees, using the tagged-photon facility at MAMI (Mainz) and the large-acceptance arrangement LARA. The data are in good agreement with the dispersion theory based on the SAID-SM99K parameterization of photo-meson amplitudes. From the subset of data between 280 and 360 MeV the resonance pion-photoproduction amplitudes were evaluated leading to the multipole E2/M1 ratio EMR(340 MeV) = (-1.6 +/- 0.4(stat+syst) +/- 0.2(model))% From all data below 455 MeV the proton's backward spin polarizability was determined to be gamma pi = (-37.9 +/- 0.6(stat+syst) +/- 3.5(model)) x 10(-4) fm(4). (C) 2001 Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0370-2693(01)00231-3"],["dc.identifier.isi","000167817400002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27805"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0370-2693"],["dc.title","Compton scattering by the proton"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cytogenetic and Genome Research"],["dc.bibliographiccitation.volume","125"],["dc.contributor.author","Grzmil, Pawel"],["dc.contributor.author","Konietzko, J."],["dc.contributor.author","Boehm, D."],["dc.contributor.author","Hoelter, Sabine M."],["dc.contributor.author","Aguilar-Pimentel, Juan Antonio"],["dc.contributor.author","Javaheri, A."],["dc.contributor.author","Kalaydjiev, S."],["dc.contributor.author","Adler, Thure"],["dc.contributor.author","Bolle, I."],["dc.contributor.author","Adham, Ibrahim M."],["dc.contributor.author","Dixkens, C."],["dc.contributor.author","Wolf, S."],["dc.contributor.author","Fuchs, H."],["dc.contributor.author","Gailus-Durner, Valerie"],["dc.contributor.author","Wurst, Wolfgang"],["dc.contributor.author","Ollert, Markus W."],["dc.contributor.author","Busch, D. H."],["dc.contributor.author","Schulz, H."],["dc.contributor.author","de Angelis, Martin Hrabe"],["dc.contributor.author","Burfeind, Peter"],["dc.date.accessioned","2018-11-07T08:34:19Z"],["dc.date.available","2018-11-07T08:34:19Z"],["dc.date.issued","2009"],["dc.format.extent","285"],["dc.identifier.doi","10.1159/000254152"],["dc.identifier.isi","000271321600007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17784"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1424-8581"],["dc.title","Targeted Disruption of the Mouse Npal3 Gene Leads to Deficits in Behavior, Increased IgE Levels, and Impaired Lung Function (vol 125, pg 186, 2009)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]